View more in
Health

After Controversial AD Drug Win, Biogen's Retinal Gene Therapy Flops

biospace.com
 2021-06-15

Cover picture for the articlePivoting from conflicting and controversial press over its recently approved Alzheimer’s disease treatment, Biogen has announced yesterday that its gene therapy drug timrepigene emparvovec has failed to show a clinically meaningful benefit for a rare inherited eye disease in a Phase III trial. The late-stage STAR study enrolled 169 adult...

www.biospace.com

Comments / 0

Comments / 0